Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BMRN 
Biomarin Pharmaceutical Inc (BMRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: BMRN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -3.17% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.63B USD | Price to earnings Ratio 32.33 | 1Y Target Price 96.77 |
Price to earnings Ratio 32.33 | 1Y Target Price 96.77 | ||
Volume (30-day avg) 1593802 | Beta 0.33 | 52 Weeks Range 60.63 - 94.85 | Updated Date 03/30/2025 |
52 Weeks Range 60.63 - 94.85 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14.96% | Operating Margin (TTM) 34.42% |
Management Effectiveness
Return on Assets (TTM) 5.15% | Return on Equity (TTM) 8.05% |
Valuation
Trailing PE 32.33 | Forward PE 17.89 | Enterprise Value 13094118594 | Price to Sales(TTM) 4.78 |
Enterprise Value 13094118594 | Price to Sales(TTM) 4.78 | ||
Enterprise Value to Revenue 4.59 | Enterprise Value to EBITDA 20.13 | Shares Outstanding 190776992 | Shares Floating 178454762 |
Shares Outstanding 190776992 | Shares Floating 178454762 | ||
Percent Insiders 0.96 | Percent Institutions 98.66 |
Analyst Ratings
Rating 4.35 | Target Price 97.66 | Buy 7 | Strong Buy 14 |
Buy 7 | Strong Buy 14 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biomarin Pharmaceutical Inc
Company Overview
History and Background
BioMarin Pharmaceutical Inc. was founded in 1997. It focuses on developing and commercializing therapies for serious and life-threatening rare genetic diseases.
Core Business Areas
- Rare Genetic Diseases: Develops and commercializes therapies for rare genetic diseases, focusing on enzyme replacement therapies and gene therapies.
Leadership and Structure
The company is led by Jean-Jacques Bienaime, Chairman and CEO. It operates with a functional organizational structure, with departments for research, development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Vimizim (elosulfase alfa): Vimizim is an enzyme replacement therapy for Morquio A syndrome (MPS IVA). Competitors include therapies focusing on symptom management, not direct enzyme replacement. Revenue for 2023 was approximately $674.8 million. The market share of this product is approximately 70% for MPS IVA enzyme replacement therapy.
- Naglazyme (galsulfase): Naglazyme is an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI). It has a significant market share in the MPS VI enzyme replacement therapy space. Revenue for 2023 was approximately $431.9 million. Competitors in this market are Sanofi's Aldurazyme (laronidase).
- Voxzogo (vosoritide): Voxzogo is a C-type natriuretic peptide (CNP) analog approved for children with achondroplasia. This treatment has recently increased the companies' revenue. Revenue for 2023 was approximately $625.6 million. There are few direct competitors in the achondroplasia treatment market.
- Aldurazyme: Aldurazyme is an enzyme replacement therapy for Mucopolysaccharidosis I (MPS I). BioMarin has the rights to this product in markets outside of the United States through a collaboration with Sanofi. This collaboration contributes a significant portion of revenue. Main competitors within this space are Enzyme Replacement Therapies
Market Dynamics
Industry Overview
The industry is characterized by high barriers to entry, due to the complex regulatory environment and the need for specialized knowledge. The industry is growing due to increased awareness of rare diseases and advances in genetic research.
Positioning
BioMarin is a leader in the rare genetic disease treatment market, with a strong portfolio of approved products and a robust pipeline of potential therapies.
Total Addressable Market (TAM)
The total addressable market for rare disease therapeutics is estimated to be over $200 billion. BioMarin is well-positioned to capture a significant portion of this market, given its strong product portfolio and focus on innovative therapies.
Upturn SWOT Analysis
Strengths
- Strong portfolio of approved products for rare genetic diseases
- Robust pipeline of potential therapies
- Experienced management team
- Established commercial infrastructure
- Strong brand reputation
Weaknesses
- High dependence on a limited number of products
- Risk of clinical trial failures
- Exposure to regulatory risks
- High R&D expenses
- Competition from larger pharmaceutical companies
Opportunities
- Expanding into new geographic markets
- Developing new therapies for additional rare diseases
- Acquiring complementary businesses
- Leveraging gene therapy technologies
- Partnerships and collaborations
Threats
- Increasing competition from biosimilars and generics
- Changes in regulatory requirements
- Pricing pressures from payers
- Economic downturns
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- SANOY (SNY)
- REGENXBIO (RGNX)
- Amicus Therapeutics (FOLD)
Competitive Landscape
BioMarin has a strong competitive position in the rare genetic disease market, but faces competition from larger pharmaceutical companies with greater resources and expertise. BioMarin's focus on specific rare diseases and innovative therapies gives it a competitive advantage.
Major Acquisitions
Prosensa Holding N.V.
- Year: 2014
- Acquisition Price (USD millions): 680
- Strategic Rationale: Acquired Prosensa to obtain drisapersen, a potential treatment for Duchenne muscular dystrophy (DMD). Although drisapersen faced regulatory challenges, the acquisition broadened BioMarin's pipeline in neuromuscular disorders.
Growth Trajectory and Initiatives
Historical Growth: BioMarin has experienced significant revenue growth over the past decade, driven by the commercial success of its approved products.
Future Projections: Analysts project continued revenue growth, driven by new product launches and label expansions. The company's pipeline of potential therapies is expected to contribute to future growth.
Recent Initiatives: BioMarin has been focused on expanding its pipeline through internal R&D and strategic acquisitions. The company is also investing in gene therapy technologies.
Summary
BioMarin is a leading biopharmaceutical company specializing in therapies for rare genetic diseases, with a strong portfolio and pipeline. Its revenue is growing, but it relies on limited products, faces R&D risks, and competition from larger firms. Recent initiatives focus on pipeline expansion and gene therapy. It maintains a healthy balance sheet and cash flow, although its shareholder returns have been inconsistent.
Similar Companies
- SANOY
- RGNX
- FOLD
- HZNP
- VRTX
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data is approximate and based on available industry reports and estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomarin Pharmaceutical Inc
Exchange NASDAQ | Headquaters San Rafael, CA, United States | ||
IPO Launch date 1999-07-23 | President, CEO & Director Mr. Alexander Hardy | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3040 | Website https://www.biomarin.com |
Full time employees 3040 | Website https://www.biomarin.com | ||
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.